develop
therapeut
agent
sever
acut
respiratori
syndrom
sar
viral
infect
use
short
interf
rna
sirna
inhibitor
exemplifi
power
new
mean
combat
emerg
infecti
diseas
potent
sirna
inhibitor
sar
coronaviru
scv
vitro
evalu
efficaci
safeti
rhesu
macaqu
macaca
mulatta
sar
model
use
clinic
viabl
deliveri
compar
three
dose
regimen
observ
sarslik
symptom
measur
scv
rna
presenc
lung
histopatholog
immunohistochemistri
consist
show
sirnamedi
antisar
efficaci
either
prophylact
therapeut
regimen
sirna
use
provid
relief
scv
infectioninduc
fever
diminish
scv
viral
level
reduc
acut
diffus
alveoli
damag
mgkg
accumul
dosag
sirna
show
sign
sirnainduc
toxic
result
suggest
clinic
investig
warrant
illustr
prospect
sirna
enabl
massiv
reduct
develop
time
new
target
therapeut
agent
outbreak
sar
pose
urgent
need
understand
diseas
pathogenesi
biolog
caus
agent
identifi
scv
individu
sar
usual
develop
high
fever
follow
sever
clinic
symptom
includ
acut
respiratori
distress
syndrom
diffus
alveolar
damag
dad
autopsi
contain
sar
achiev
larg
tradit
quarantin
sanit
measur
sar
newli
emerg
diseas
safe
effect
vaccin
yet
avail
although
candid
vaccin
advanc
monkey
model
clinic
test
treat
individu
sar
combin
exist
drug
includ
ribavirin
antibiot
antiinflammatori
steroid
immun
stimul
achiev
clinic
success
mani
ongo
effort
develop
sarsspecif
drug
screen
smallmolecul
inhibitor
current
biolog
approach
clarifi
strength
weak
approach
base
ultim
success
rate
time
cost
incur
identif
scv
caus
pathogen
sar
achiev
mainli
demonstr
exposur
cynomolgu
macaqu
scv
result
symptom
similar
individu
sar
meanwhil
develop
macaqu
model
becam
import
understand
sar
pathogenesi
also
evalu
potenti
vaccin
therapeut
recent
rhesu
macaqu
sar
model
establish
intranas
instil
scv
strain
show
mani
element
patholog
similar
individu
sar
pathogenesi
includ
elev
bodi
temperatur
low
appetit
acut
dad
clearli
visibl
infect
dpi
somewhat
wors
sever
macaqu
sar
model
offer
ideal
model
evalu
therapeut
candid
search
develop
antivir
agent
directli
viral
genom
sequenc
led
short
interf
rna
sirna
mediat
sequenceselect
inhibit
known
rna
interfer
rnai
report
screen
sirna
candid
target
element
throughout
entir
scv
genom
identifi
sever
sirna
activ
scvinfect
fatal
rhesu
monkey
kidney
cell
distinct
activ
sirna
report
lab
howev
translat
vitro
sirna
activ
clinic
use
therapeut
depend
clinic
accept
mean
administr
therefor
sirna
show
promin
prophylact
therapeut
activ
cell
cultur
refer
evalu
vivo
first
use
report
gene
assay
mice
subsequ
use
clinic
accept
intranas
administr
recent
establish
rhesu
macaqu
sar
model
studi
provid
strong
evid
sirna
agent
potent
prophylact
therapeut
treatment
sar
infect
lack
toxic
nonhuman
primat
model
result
support
grow
expect
sirna
fulfil
need
move
rapidli
gene
sequenc
target
therapeut
agent
mani
previous
intract
diseas
target
develop
therapeut
agent
sever
acut
respiratori
syndrom
sar
viral
infect
use
short
interf
rna
sirna
inhibitor
exemplifi
power
new
mean
combat
emerg
infecti
diseas
potent
sirna
inhibitor
sar
coronaviru
scv
vitro
evalu
efficaci
safeti
rhesu
macaqu
macaca
mulatta
sar
model
use
clinic
viabl
deliveri
compar
three
dose
regimen
observ
sarslik
symptom
measur
scv
rna
presenc
lung
histopatholog
immunohistochemistri
consist
show
sirnamedi
antisar
efficaci
either
prophylact
therapeut
regimen
sirna
use
provid
relief
scv
infectioninduc
fever
diminish
scv
viral
level
reduc
acut
diffus
alveoli
damag
mgkg
accumul
dosag
sirna
show
sign
sirnainduc
toxic
result
suggest
clinic
investig
warrant
illustr
prospect
sirna
enabl
massiv
reduct
develop
time
new
target
therapeut
agent
outbreak
sar
pose
urgent
need
understand
diseas
pathogenesi
biolog
caus
agent
identifi
scv
individu
sar
usual
develop
high
fever
follow
sever
clinic
symptom
includ
acut
respiratori
distress
syndrom
diffus
alveolar
damag
dad
autopsi
contain
sar
achiev
larg
tradit
quarantin
sanit
measur
sar
newli
emerg
diseas
safe
effect
vaccin
yet
avail
although
candid
vaccin
advanc
monkey
model
clinic
test
treat
individu
sar
combin
exist
drug
includ
ribavirin
antibiot
antiinflammatori
steroid
immun
stimul
achiev
clinic
success
mani
ongo
effort
develop
sarsspecif
drug
screen
smallmolecul
inhibitor
current
biolog
approach
clarifi
strength
weak
approach
base
ultim
success
rate
time
cost
incur
identif
scv
caus
pathogen
sar
achiev
mainli
demonstr
exposur
cynomolgu
macaqu
scv
result
symptom
similar
individu
sar
meanwhil
develop
macaqu
model
becam
import
understand
sar
pathogenesi
also
evalu
potenti
vaccin
therapeut
recent
rhesu
macaqu
sar
model
establish
intranas
instil
scv
strain
show
mani
element
patholog
similar
individu
sar
pathogenesi
includ
elev
bodi
temperatur
low
appetit
acut
dad
clearli
visibl
infect
dpi
somewhat
wors
sever
macaqu
sar
model
offer
ideal
model
evalu
therapeut
candid
search
develop
antivir
agent
directli
viral
genom
sequenc
led
short
interf
rna
sirna
mediat
sequenceselect
inhibit
known
rna
interfer
rnai
report
screen
sirna
candid
target
element
throughout
entir
scv
genom
identifi
sever
sirna
activ
scvinfect
fatal
rhesu
monkey
kidney
cell
distinct
activ
sirna
report
lab
howev
translat
vitro
sirna
activ
clinic
use
therapeut
depend
clinic
accept
mean
administr
therefor
sirna
show
promin
prophylact
therapeut
activ
cell
cultur
refer
evalu
vivo
first
use
report
gene
assay
mice
subsequ
use
clinic
accept
intranas
administr
recent
establish
rhesu
macaqu
sar
model
studi
provid
strong
evid
sirna
agent
potent
prophylact
therapeut
treatment
sar
infect
lack
toxic
nonhuman
primat
model
result
support
grow
expect
sirna
fulfil
need
move
rapidli
gene
sequenc
target
therapeut
agent
mani
previous
intract
diseas
target
two
sirna
duplex
target
scv
genom
spike
proteincod
region
fig
respect
chosen
vivo
studi
follow
reason
target
sequenc
show
homolog
strain
use
cellcultur
studi
strain
use
macaqu
model
anoth
publish
scv
strain
isol
differ
phase
scv
evolut
recent
defin
wide
geograph
distribut
around
world
ii
two
potent
inhibitor
reduc
scv
replic
cell
among
set
activ
sirna
duplex
select
sirna
duplex
target
entir
scv
genom
iii
synergist
antiscv
activ
observ
combin
appli
cellcultur
studi
show
strongest
prophylact
therapeut
effect
fig
c
iv
target
sequenc
share
homolog
human
genom
avoid
potenti
nonspecif
knockdown
endogen
gene
individu
receiv
type
treatment
addit
two
unrel
sirna
duplex
sicona
siconb
homolog
either
human
genom
sar
genom
valid
cellcultur
studi
show
rnai
activ
scv
inhibit
chosen
neg
control
supplementari
fig
onlin
duplex
activ
mous
lung
insur
vivo
activ
combin
clinic
viabl
deliveri
method
first
establish
luciferasebas
report
gene
system
contain
target
sequenc
cytomegaloviru
promot
luciferas
code
region
cotransfect
pciscluc
cultur
cell
confirm
specif
knock
luciferas
express
data
shown
identifi
clinic
viabl
carrier
sirna
deliveri
mous
lung
select
two
carrier
current
clinic
use
solut
infasurf
solut
appli
deliveri
dna
sirna
anim
model
twentyfour
hour
intratrach
administr
mg
pciscluc
plasmid
dna
mg
ml
infasurf
solut
balbc
mous
lung
analyz
luciferas
express
lung
tissu
codeliveri
pciscluc
plasmid
solut
result
higher
level
report
gene
express
stronger
rnai
effect
deliv
infasurf
solut
fig
note
transittko
polyethyleneimin
report
carrier
intranas
intratrach
intraven
deliveri
sirna
mous
model
treatment
influenza
viru
respiratori
syncyti
viru
infect
carrier
feasibl
clinic
use
especi
polyethyleneimin
induc
sever
lung
inflamm
either
intraven
intratrach
deliveri
mice
base
experi
data
shown
literatur
report
substanti
silenc
effect
achiev
mous
lung
strongli
support
potent
inhibitor
scv
rna
also
effect
carrier
sirna
mammalian
respiratori
tract
addit
lack
visibl
lung
damag
intratrach
deliveri
mg
sirna
mg
plasmid
dna
togeth
provid
safe
baselin
sirna
dose
respiratori
tract
larger
mammal
use
total
macaqu
studi
includ
five
group
n
infect
scv
one
individu
without
scv
infect
five
group
consist
two
control
groupsvir
infect
control
nonspecif
sirna
controland
three
treatment
regimen
groupsprophylact
treatment
codeliveri
treatment
postexposur
treatment
anesthet
macaqu
infect
scv
dosag
time
halfmaxim
tissu
cultur
infecti
dose
tcid
ml
pb
solut
intranas
instil
also
administ
combin
sicona
siconb
siconab
rout
mg
per
dose
ml
solut
differ
dose
regimen
tabl
initi
observ
indic
scvinfect
macaqu
develop
sarslik
symptom
control
group
show
greater
sever
report
cynomolgu
macaqu
sar
model
exampl
macaqu
viral
infect
control
group
nonspecif
sirna
control
group
develop
elev
bodi
temperatur
case
last
entir
studi
period
contrast
macaqu
group
show
milder
elev
bodi
temperatur
anim
display
loss
appetit
becam
agit
aggress
gener
observ
lung
histolog
specimen
indic
lung
lesion
develop
congest
palpabl
nodul
scatter
distribut
local
particularli
posterior
part
differ
lobe
sever
lung
damag
occur
focal
surround
larg
area
obviou
patholog
wherea
milder
lung
damag
appear
smaller
area
patholog
better
character
patholog
chang
adopt
sixgrad
score
system
describ
sever
lung
damag
least
sever
sever
ii
iii
iv
v
vi
fig
liver
enzymat
analysi
show
evid
increas
alanin
aminotransferas
lactic
acid
dehydrogenas
creatin
kinas
aspart
aminotransferas
scv
infect
macaqu
everi
test
group
dpi
notabl
routin
blood
examin
indic
mark
increas
hemoglobin
platelet
scvinfect
macaqu
contradictori
report
sar
macaqu
model
sarsinfect
individu
supplementari
tabl
onlin
mechan
underli
differ
behavior
primat
sar
model
requir
investig
scvinduc
dad
lower
airway
usual
observ
individu
sar
diseas
wherea
scvinfect
macaqu
lung
start
develop
acut
dad
dpi
histopatholog
immunohistochem
ihc
inspect
found
lung
dpi
display
acut
dad
variou
degre
sever
typic
featur
scv
infectioninduc
lung
damag
includ
broken
alveolar
wall
interstiti
edema
fig
hyalin
membran
format
along
alveoli
pneumocyt
desquam
fig
damag
alveolu
fill
hemorrhag
pneumocyt
nuclear
enlarg
promin
nucleolu
amphophil
granular
cytoplasm
fig
interstiti
infiltr
neutrophil
lymphocyt
macrophag
fig
within
damag
lung
tissu
identifi
viralinfect
pneumocyt
infiltr
neutrophil
lymphocyt
monocyt
use
ihc
stain
keratin
fig
fig
data
shown
characterist
similar
observ
individu
sar
sar
macaqu
model
therefor
rhesu
macaqu
model
provid
ideal
system
evalu
new
therapeut
agent
sar
bodi
temperatur
infect
macaqu
key
indic
sever
sarslik
symptom
also
effect
treatment
record
bodi
temperatur
everi
anim
daili
kill
comparison
mean
bodi
temperatur
five
group
fig
reveal
significantli
lower
temperatur
treat
group
prophylact
codeliveri
postexposur
treatment
group
versu
control
group
viral
infect
nonspecif
sirna
group
temperatur
indic
fever
statu
prophylact
treatment
group
lowest
temperatur
close
normal
bodi
temperatur
rhesu
monkey
examin
distribut
averag
bodi
temperatur
time
point
throughout
entir
period
trend
regress
fig
found
viral
infect
nonspecif
sirna
control
group
consist
elev
temperatur
macaqu
viral
infect
control
group
high
fever
dpi
fever
last
macaqu
kill
dpi
patholog
analysi
time
show
sever
lung
damag
score
similar
situat
seen
macaqu
nonspecif
sirna
group
comparison
mean
bodi
temperatur
trend
regress
clearli
show
prophylact
therapeut
effect
suppress
fever
induc
scv
infect
addit
inhibitori
effect
also
result
lower
scvspecif
igg
titer
blood
sampl
fig
detect
scvspecif
igg
level
viral
control
nonspecif
sirna
control
group
earli
dpi
codeliveri
postexposur
treatment
group
abl
detect
scvspecif
igg
titer
group
dpi
sirna
protect
lung
sever
acut
dad
viral
infect
control
group
macaqu
sever
acut
dad
patholog
chang
larg
portion
lung
includ
interstiti
infiltr
lung
damag
score
macaqu
nonspecif
sirna
control
group
show
even
sever
acut
dad
larg
portion
lung
massiv
cell
infiltr
alveoli
shrinkag
sheet
septa
fusion
necrot
lesion
hemorrhag
septa
extens
loss
alveolar
bronchiolar
epithelium
repres
typic
lung
damag
score
worst
case
among
scvexpos
macaqu
macaqu
viral
infect
nonspecif
sirna
control
group
suffer
sever
acut
dad
lung
damag
score
hand
lung
tissu
three
group
prophylact
codeliveri
postexposur
treatment
group
show
rel
mild
sever
acut
dad
none
show
lung
damag
beyond
score
section
macaqu
show
alveolar
wall
collaps
acut
diffus
interstiti
injuri
interstiti
edema
arrow
earli
stage
diseas
b
section
macaqu
show
hyalin
membran
format
arrow
along
alveoli
pneumocyt
desquam
c
lung
section
stain
h
e
origin
magnif
c
section
macaqu
show
damag
alveoli
fill
hemorrhag
inflammatori
cell
upper
arrow
pneumocyt
nuclear
enlarg
promin
nucleolu
amphophil
granular
cytoplasm
result
focal
giantcel
format
lower
arrow
section
macaqu
show
inflammatori
cell
includ
neutrophil
lymphocyt
macrophag
monocyt
present
damag
alveoli
e
ihc
stain
scvinfect
monkey
lung
section
keratinspecif
monoclon
antibodi
indic
epitheli
origin
pneumocyt
arrow
origin
magnif
f
ihc
stain
scvinfect
monkey
lung
section
monoclon
antibodi
indic
microphag
infiltr
arrow
origin
magnif
indic
macaqu
protect
sever
acut
dad
fig
analyz
oropharyng
swab
sampl
dpi
quantit
realtim
pcr
qrtpcr
show
scv
viral
rna
detect
sampl
viral
infect
nonspecif
sirna
control
group
undetect
sampl
treatment
group
fig
result
indic
possibl
inhibit
scv
infect
replic
viral
rna
degrad
upper
airway
epitheli
cell
three
posit
sampl
treatment
group
suggest
dose
regimen
unabl
total
elimin
scv
infect
histopatholog
analys
macaqu
inde
shown
degre
lung
damag
score
qrtpcr
detect
randomli
select
lung
tissu
specimen
also
show
presenc
scv
rna
supplementari
fig
onlin
also
appli
oropharyng
swab
sampl
activ
viral
rescu
vero
cell
cultur
show
sampl
five
group
posit
live
scv
particl
evalu
scv
infect
deeper
lung
care
inspect
ihc
stain
imag
lung
section
scv
antigenspecif
monoclon
antibodi
sampl
viral
infect
nonspecif
sirna
group
present
much
infect
cell
fig
group
fig
scvinfect
cell
includ
type
pneumocyt
fig
e
type
ii
pneumocyt
fig
macrophag
fig
presenc
consist
observ
previou
studi
macaqu
model
individu
sar
count
infect
cell
lung
section
compar
number
five
group
lung
three
treatment
group
significantli
lower
count
scvinfect
cell
fig
indic
sirna
treatment
abl
inhibit
scv
replic
spread
within
monkey
lung
sirna
safe
prophylact
therapeut
treatment
evalu
new
biolog
agent
sirna
therapeut
util
depend
efficaci
treat
diseas
also
toler
safeti
studi
put
efficaci
safeti
equal
consider
order
defin
therapeut
window
use
sirna
antisar
agent
airway
administr
choic
dosag
mgkg
base
mous
studi
describ
studi
report
antisens
oligom
observ
behavior
pattern
rhesu
macaqu
entir
studi
examin
organ
kill
anim
variou
sirna
dose
regimen
safeti
concern
aros
treatment
group
lack
evid
inflamm
toxic
attribut
scv
infect
total
accumul
dosag
sirna
administr
individu
macaqu
rang
mgkg
mgkg
caus
visibl
differ
appear
behavior
sign
organ
damag
examin
autopsi
necropsi
addit
found
statist
signific
differ
intern
organ
coeffici
among
five
group
supplementari
tabl
onlin
report
potenti
offtarget
effect
sirna
agent
mostli
base
cellcultur
experi
without
evid
vivo
sirna
toxic
result
routin
blood
examin
liver
enzymat
analysi
found
increas
alanin
aminotransferas
lactic
acid
dehdryogenas
creatin
kinas
aspart
dehydrogenas
hemoglobin
platelet
level
blood
sampl
increas
scvinfect
macaqu
without
sirna
treatment
probabl
result
viral
infect
rather
sirna
treatment
supplementari
tabl
onlin
although
concern
remain
whether
macaqu
sar
model
clinic
relev
rhesu
macaqu
model
use
use
highvirul
scv
strain
ref
cynomolgu
macaqu
sar
model
clear
clinic
relev
model
found
paramet
studi
includ
elev
bodi
temperatur
lung
patholog
scv
antigen
detect
epithelialorigin
type
pneumocyt
type
ii
pneumocyt
macrophag
provid
strong
support
model
attribut
requir
evalu
sirna
candid
therapeut
agent
administ
intranas
rout
scv
challeng
prophylact
concurr
earli
postexposur
treatment
within
period
dpi
three
differ
treatment
regimen
achiev
potent
suppress
scvinduc
sar
pathogenesi
detect
scv
rna
genom
rtpcr
show
oropharyng
swab
sampl
treat
group
posit
versu
sampl
control
group
similarli
use
ihc
detect
scvinfect
cell
count
significantli
decreas
lung
section
treat
group
along
reduc
viral
load
substanti
reduct
sarslik
symptom
lung
histopatholog
includ
significantli
lower
mean
bodi
temperatur
group
lung
damag
beyond
score
contrast
mean
bodi
temperatur
control
group
indic
fever
statu
along
substanti
lung
damag
design
studi
investig
sirnamedi
antiscv
effect
upper
airway
deep
lung
scvexpos
macaqu
occur
earli
phase
viral
infect
diseas
progress
impact
earli
phase
scv
infect
first
shown
mucos
epitheli
cell
upper
respiratori
tract
expect
scv
administ
intranas
instil
sirna
dose
complet
within
first
antisar
efficaci
could
result
one
follow
three
mechan
protect
cell
scv
infect
degrad
scv
mrna
inhibit
viral
protein
synthesi
infect
cell
obstruct
scv
genom
replic
spread
uninfect
cell
consid
sarsspecif
neutral
antibodi
scvinfect
macaqu
detect
earli
dpi
specul
clinic
benefit
sirnamedi
antisar
activ
observ
studi
consequ
combin
activ
sirna
agent
neutral
antibodi
suggest
multipl
antivir
mechan
oper
deliv
scv
infect
prophylact
treatment
group
use
singl
dose
abl
achiev
compar
inhibitori
effect
codeliveri
postexposur
treatment
group
prophylact
antiscv
activ
result
lower
bodi
temperatur
milder
lung
damag
less
viral
rna
detect
lower
number
scvinfect
cell
lung
comparison
codeliveri
postexposur
treatment
group
mechan
action
might
result
direct
degrad
viral
rna
preexist
within
upper
airway
cell
upon
entri
viral
particl
block
replic
spread
scv
particl
addit
cellular
antivir
activ
induc
sirna
transfect
interferon
respons
may
also
role
interferon
respons
sirna
duplex
cellcultur
studi
rais
concern
specif
rnai
anim
recent
vivo
studi
use
sirna
rsv
mous
lung
show
lack
detect
sirnainduc
interferon
observ
also
echo
report
intraven
sirna
deliveri
mice
result
lack
interferon
induct
vivo
siconab
use
studi
contain
neither
motif
suspect
immunostimulatori
element
associ
transfect
reagent
find
antiscv
activ
use
control
siconab
therefor
conclud
antisar
activ
probabl
result
scv
rna
degrad
within
cell
throughout
pulmonari
tract
treat
macaqu
releas
proinflammatori
cytokin
alveolar
macrophag
propos
promin
role
sar
pathogenesi
point
intervent
presenc
hemophagocytosi
interferongrel
cytokin
storm
individu
sar
complic
understand
sar
pathogenesi
also
argu
use
interferon
therapi
clinic
treatment
despit
studi
cell
cultur
macaqu
model
individu
sar
show
inhibit
scv
interferon
treatment
contrast
proinflammatori
cytokin
treatment
intranas
deliveri
sirna
offer
uniqu
method
highspecif
inhibit
scv
minim
induct
proinflammatori
cytokin
antivir
respons
may
help
avoid
exacerb
symptom
lung
damag
present
evid
strong
antisar
activ
without
visibl
advers
effect
intranas
administr
clinic
viabl
aqueou
solut
nonhuman
primat
sar
model
data
suggest
clinic
test
agent
sar
treatment
warrant
work
also
show
tremend
potenti
sirna
enabl
rapid
develop
treatment
emerg
infecti
agent
power
target
therapeut
act
level
gene
express
scv
rhesu
macaqu
model
scv
strain
isol
individu
peke
union
medic
hospit
propag
cultur
vero
cell
rhesu
macaqu
macaca
mulatta
sar
model
develop
use
intranas
inocul
scv
perform
studi
biosafeti
level
laboratori
exclus
assign
scv
research
institut
laboratori
anim
scienc
chines
academi
medic
scienc
approv
anim
studi
protocol
institut
anim
welfar
committe
inocul
monkey
ml
intranas
instil
mimick
natur
rout
scv
infect
human
sar
also
deliv
mg
siconab
ml
solut
intranas
instil
confirm
monkey
neg
presenc
scvspecif
antibodi
scv
challeng
scv
challeng
sirna
dose
observ
clinic
sign
macaqu
daili
includ
bodi
temperatur
size
lymph
node
bodi
weight
cough
sneez
appetit
aggress
etc
dpi
took
oropharyng
swab
scvchalleng
monkey
detect
viral
rna
use
rtpcr
viral
reisol
collect
blood
sampl
dpi
routin
laboratori
examin
includ
liver
enzymat
analysi
detect
scvspecif
antibodi
elisa
diagnosi
kit
detect
scvspecif
igg
igm
hau
da
biotech
use
accord
manufactur
protocol
collect
lung
necropsi
macaqu
dpi
histopatholog
analys
also
collect
organ
inspect
morpholog
appear
follow
comparison
intern
organ
coeffici
group
base
wet
weight
organ
per
g
averag
bodi
weight
supplementari
tabl
onlin
sirna
duplex
select
two
scvspecif
sirna
duplex
base
previou
vitro
studi
use
mixtur
consist
equal
amount
sirna
duplex
also
use
pair
control
sirna
duplex
sicona
siconb
mixtur
siconab
use
anoth
pair
unrel
control
sirna
duplex
siconc
sicond
mixtur
mous
studi
siconcd
sirna
duplex
consist
two
complementari
rna
strand
dtdt
overhang
chemic
synthes
qiagen
sirna
sequenc
follow
forward
revers
forward
aaggcaauuua
revers
sicona
forward
revers
siconb
forward
revers
siconc
forward
revers
sicond
forward
revers
electron
microscopi
harvest
cell
infect
scv
without
treatment
fix
epoxi
resin
polysci
examin
ultrathin
section
nm
thick
philip
electron
microscop
kv
describ
previous
deliveri
nucleic
acid
mous
lung
divid
balbc
mice
four
group
n
test
two
carrier
solut
rnasefre
dglucos
water
wtvol
made
inhous
infasurf
solut
oni
inc
deliv
siconcd
pciscluc
plasmid
mix
mg
pciscluc
mg
correspond
sirna
ml
carrier
solut
intratrach
administ
mous
lung
construct
pciscluc
plasmid
insert
dna
fragment
contain
sequenc
dna
cytomegaloviru
promoterdriven
transcript
initi
site
luciferasecod
sequenc
h
deliveri
mice
kill
lung
tissu
harvest
homogen
ml
report
lysi
buffer
promega
use
lyse
matrix
bio
system
bio
system
speed
centrifug
rpm
min
use
ml
supernat
measur
luciferas
activ
use
luciferas
assay
kit
promega
luminomet
analyt
luminesc
laboratori
follow
manufactur
protocol
perform
anim
experi
protocol
approv
institut
anim
care
use
committe
biomed
research
institut
qrtpcr
scv
reisol
isol
total
cellular
rna
use
qiaamp
rna
isol
kit
qiagen
synthes
first
strand
cdna
use
rnase
h
revers
transcriptas
random
primer
invitrogen
accord
manufactur
protocol
forward
revers
primer
target
upstream
open
read
frame
fluoresc
probe
use
pcr
forward
revers
famagctacgag
caccagacacccttcgaaatrma
fluoresc
probe
pcr
perform
rtpcr
use
sequenc
detect
system
abi
pcr
experi
done
triplic
conduct
scv
reisol
use
swab
sampl
serial
passag
vero
cell
cultur
previous
describ
lung
histopatholog
ihc
analys
obtain
lung
tissu
block
right
upper
right
middl
lobe
perform
patholog
analysi
describ
previous
determin
sever
lung
damag
base
observ
five
differ
section
lung
readout
three
independ
pathologist
blind
experiment
condit
quantifi
patholog
chang
lung
treatment
calcul
averag
histopathlog
score
group
use
score
system
describ
dewax
waxembed
tissu
section
rehydr
ihc
analysi
describ
previous
identifi
cell
type
base
separ
stain
correspond
monoclon
antibodi
use
method
describ
previous
use
viral
antigen
detect
ihc
indic
infect
cell
collect
scvinfect
cell
count
within
microscop
imag
everi
lung
tissu
section
independ
three
readout
investig
blind
experiment
condit
compar
averag
cell
count
four
lung
group
n
statist
analysi
analyz
data
use
student
ttest
luciferas
express
mous
lung
mean
bodi
temperatur
histopatholog
score
comparison
scvinfect
cell
count
consid
result
statist
signific
p
conduct
regress
analysi
base
averag
bodi
temperatur
group
day
point
conduct
multifactor
anova
intern
organ
coeffici
access
code
genbank
scv
strain
strain
scv
complet
genom
sequenc
note
supplementari
inform
avail
natur
medicin
websit
